The CAPTIV Collaboration will bring together clinical and basic researchers to improve quality of care for men with prostate cancer. We will undertake clinical and translational studies that will determine better ways to treat early and advanced prostate cancer. The unique access to clinical specimens will allow us to perform pre-clinical studies of promising agents, perform longitudinal and prospective studies on cohorts of prostate cancer patients, and determine the effects of specific germ line mutations on prostate cancer susceptibility and outcomes.